Barr Ellison Solicitors – commercial property
Advertisement: Cambridge Network
Advertisement: EBCam mid banner
Advertisement: Wild Knight Vodka
Mid banner advertisement: BDO
Advertisement: Mogrify
Advertisement: TTP
RealVNC mid-banner general
Advertisement: Innova Systems
Advertisement EY mid banner
Advertisement: RSM
RealVNC mid banner careers
ARM Innovation Hub
Advertisement: Cambridge Corporate Finance Club
14 March, 2012 - 10:31 By News Desk

Triple power play on key disease areas


Companies at the heart of the Cambridge BioMedTech cluster have joined forces to fight respiratory and inflammatory diseases.

BioFocus and Argenta have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AZ’s research programmes in these areas.

Each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta.

Financial details were not disclosed.

Dr John Steele, VP R&I Innovative Medicines Science Unit at AstraZeneca.said: “We continue to be impressed by the strength of the BioFocus and Argenta technology platforms and the evident depth of experience of the scientists that will be engaged on our projects addressing respiratory and inflammatory conditions.”

Dr Chris Newton, SVP Galapagos Services, the parent of BioFocus, added: “Both BioFocus and Argenta have worked extensively with AstraZeneca over the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on.”

Add new comment

Newsletter Subscription

Stay informed of the latest news and features